JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120478

Pifithrin-alpha-HBr, p53 Inhibitor

Be the first to review this product! Submit a review

|

(5 Publications)

MW 367.3 Da, Purity >95%. p53 Inhibitor. Specifically blocks tumor supressor p53 transcriptional activity and can supress heat shock and glucocorticoid signalling pathways. Additionally offers protection to cells from p53 mediated apoptosis. Active in vivo; protects mice from chemotherapy side effects associated with p53 induction. Also aryl hydrocarbon receptor (AHR) agonist.
1 Images
Chemical Structure - Pifithrin-alpha-HBr, p53 Inhibitor (AB120478)
  • Chemical Structure

Lab

Chemical Structure - Pifithrin-alpha-HBr, p53 Inhibitor (AB120478)

2D chemical structure image of ab120478, Pifithrin-alpha-HBr, p53 Inhibitor

Key facts

CAS number

63208-82-2

Purity

>95%

Form

Solid

form

Molecular weight

367.3 Da

Molecular formula

C<sub>1</sub><sub>6</sub>H<sub>1</sub><sub>9</sub>BrN<sub>2</sub>OS

PubChem

9929138

Nature

Synthetic

Solubility

Soluble in DMSO to 100 mM

Biochemical name

Pifithrin-alpha

Biological description

p53 Inhibitor. Specifically blocks tumor supressor p53 transcriptional activity and can supress heat shock and glucocorticoid signalling pathways. Additionally offers protection to cells from p53 mediated apoptosis. Active in vivo; protects mice from chemotherapy side effects associated with p53 induction. Also aryl hydrocarbon receptor (AHR) agonist.

Canonical smiles

CC1=CC=C(C=C1)C(=O)CN2C3=C(CCCC3)SC2=N.Br

InChi

InChI=1S/C16H18N2OS.BrH/c1-11-6-8-12(9-7-11)14(19)10-18-13-4-2-3-5-15(13)20-16(18)17;/h6-9,17H,2-5,10H2,1H3;1H

InChiKey

HAGVCKULCLQGRF-UHFFFAOYSA-N

IUPAC Name

2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone;hydrobromide

Product details

Pifithrin-α-HBr is light senstive and it is recommended that the compound is protected from light.

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CYP1A1 and CYP1B1 are members of the cytochrome P450 family of enzymes alternatively known as AHH and aryl hydrocarbon hydroxylase. CYP1A1 has a mass of approximately 58 kDa while CYP1B1 weighs around 60 kDa. These enzymes are expressed in various tissues including the lungs liver and the gastrointestinal tract. Their mechanical role involves the oxidation of organic substances which is important for the metabolism of xenobiotics and endogenous compounds like steroids.
Biological function summary

These cytochrome P450 enzymes play a critical role in detoxifying numerous harmful compounds. They help metabolize polycyclic aromatic hydrocarbons and estrogens. CYP1A1 and CYP1B1 do not form a known multimeric complex but they do function in association with electron transfer partners like NADPH-cytochrome P450 reductase. This association aids in facilitating the enzymatic reactions important for metabolic processes.

Pathways

CYP1A1 and CYP1B1 participate prominently in the metabolic activation of procarcinogens and in estrogen metabolism pathways. These enzymes convert procarcinogens to their active carcinogenic forms influencing the risk of carcinogen-induced DNA damage. They also play a role in estrogen metabolism by hydroxylation of estrogens contributing to hormonal regulation. The pathways involve various proteins including NADPH-cytochrome P450 reductase and other members of the cytochrome P450 family.

CYP1A1 and CYP1B1 have a strong connection to cancer and glaucoma. Overexpression and polymorphisms in these enzymes are linked to an increased risk of lung cancer due to enhanced activation of carcinogens. In glaucoma mutations in CYP1B1 lead to structural changes that impair normal eye development. These connections to diseases highlight their interaction with regulatory proteins like p53 which plays a role in controlling cell proliferation and apoptosis. Understanding these relationships is important for developing targeted therapeutic strategies.

Product protocols

Publications (5)

Recent publications for all applications. Explore the full list and refine your search

Scientific reports 13:8705 PubMed37248327

2023

Streptozotocin induces renal proximal tubular injury through p53 signaling activation.

Applications

Unspecified application

Species

Unspecified reactive species

Kunihiro Nakai,Minato Umehara,Atsushi Minamida,Hiroko Yamauchi-Sawada,Yasuto Sunahara,Yayoi Matoba,Natsuko Okuno-Ozeki,Itaru Nakamura,Tomohiro Nakata,Aya Yagi-Tomita,Noriko Uehara-Watanabe,Tomoharu Ida,Noriyuki Yamashita,Michitsugu Kamezaki,Yuhei Kirita,Eiichi Konishi,Hiroaki Yasuda,Satoaki Matoba,Keiichi Tamagaki,Tetsuro Kusaba

Oxidative medicine and cellular longevity 2021:8889195 PubMed34646427

2021

Downregulation of miR-128 Ameliorates Ang II-Induced Cardiac Remodeling via SIRT1/PIK3R1 Multiple Targets.

Applications

Unspecified application

Species

Unspecified reactive species

Heqin Zhan,Feng Huang,Qian Niu,Mingli Jiao,Xumeng Han,Kaina Zhang,WenZhuo Ma,Shan Mi,Shiyu Guo,Zhenghang Zhao

Stem cell research & therapy 12:169 PubMed33691791

2021

Transcriptional factor FoxM1-activated microRNA-335-3p maintains the self-renewal of neural stem cells by inhibiting p53 signaling pathway via Fmr1.

Applications

Unspecified application

Species

Unspecified reactive species

Jiaoying Jia,Yan Cui,Zhigang Tan,Min Liu,Yugang Jiang

Scientific reports 10:4441 PubMed32157166

2020

Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Masahiro Uehara,Tetsuro Kusaba,Tomoharu Ida,Kunihiro Nakai,Tomohiro Nakata,Aya Tomita,Noriko Watanabe-Uehara,Kisho Ikeda,Takashi Kitani,Noriyuki Yamashita,Yuhei Kirita,Satoaki Matoba,Benjamin D Humphreys,Keiichi Tamagaki

Cancer cell international 17:98 PubMed29093644

2017

Synergistic anticancer effect of combined crocetin and cisplatin on KYSE-150 cells via p53/p21 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Sheng Li,Xiu-Yin Shen,Ting Ouyang,Yuhua Qu,Tao Luo,Hua-Qiao Wang
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com